Abstract 507P
Background
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent a highly effective treatment for advanced non-small-cell lung cancer (NSCLC) with active mutations of the EGFR gene. However, most patients develop acquired resistance to EGFR-TKIs. The T790M mutation has been found to be associated with almost 50% of patients who acquired resistance to first- or second- generation EGFR-TKIs. The role of immune checkpoint inhibitors (ICIs) for patients without a T790M mutation or patients with a T790M mutation who have progressed after T790M inhibitor therapy remains unclear.
Methods
We retrospectively evaluated the clinical effects of ICIs for EGFR mutated non- squamous NSCLC patients who were treated after developing resistance to first- or second- generation EGFR-TKIs at five institutions in Japan. Patients treated with EGFR-TKI between May 2016 and October 2018 were enrolled. Patients who used a third-generation EGFR-TKI before using prior generations were excluded.
Results
Of the 58 patients identified, 21 were positive for T790M, and all were developing resistance to both third- and prior generation EGFR-TKIs. The objective response and disease control rates for ICIs were 13.8% and 55.2% respectively, and T790M-negative patients had numerically greater responses than T790M-positive patients (16.2% versus 9.5% and 62.1% versus 42.9%, p = 0.70 and p = 0.18, respectively). T790M-negative patients were associated with a clinically meaningfully longer median progression-free survival than were T790M-positive patients (4.4 months versus 1.8 months, p = 0.061).
Conclusions
T790M-negative status after development of acquired resistance to EGFR-TKIs tended to be associated with benefit from immunotherapy in this retrospective analysis.
Clinical trial identification
UMIN000028989.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca K. K.
Disclosure
F. Imamura: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract